SCHEMBL6233534

SCHEMBL6233534

CC(=O)N1CCC2(CCCCC2)C1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 6/20 0.51
CYP2C19 P33261 3/20 0.51
HIF1A Q16665 2/20 0.51
CYP2D6 P10635 6/20 0.50
HSD11B1 P28845 6/20 0.50
HSD17B10 Q99714 3/20 0.50
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GRM5 P41594 1/20 0.49
CYP1A2 P05177 3/20 0.48
TSHR P16473 3/20 0.48
USP2 O75604 2/20 0.48
CYP2C9 P11712 2/20 0.48
OPRM1 P35372 1/20 0.47
OPRL1 P41146 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16852620 0.98 CYP3A4 (0.53) CYP3A4CYP2C19HIF1ACYP2D6HSD11B1
SCHEMBL12335229 0.92 GRM5 (0.58) CYP3A4CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL5986519 0.89 OPRM1 (0.54) CYP3A4CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL10466780 0.87 USP2 (0.53) CYP3A4CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL18711489 0.85 CYP3A4 (0.55) CYP3A4CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL18711490 0.85 USP2 (0.55) CYP3A4CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL24279550 0.85 CYP3A4 (0.46) CYP3A4CYP2C19HIF1ACYP2D6HSD11B1
SCHEMBL23763347 0.83 CYP1A2 (0.52) CYP3A4CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL21078057 0.82 CYP3A4 (0.47) CYP3A4CYP2C19HIF1ACYP2D6HSD17B10
SCHEMBL4066199 0.81 HSD11B1 (0.54) CYP3A4CYP2C19HIF1AHSD11B1GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1485352-B1 AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN SANOL ARZNEI SCHWARZ GMBH (DE) 2005-06-29 EP claimed
EP-1520854-A2 Aza-Spirocompounds for the treatment of pain SCHWARZ PHARMA AG (DE) 2005-04-06 EP claimed
EP-3842431-A1 [1,2,4]TRIAZOLO[1,5-A]PYRIDINE COMPOUND AS JAK INHIBITOR AND APPLICATION THEREOF Zhuhai United Laboratories Co., Ltd (CN) 2021-06-30 EP disclosed
US-20050288351-A1 Azaspiro compounds for the treatment of pain SCHWARZ PHARMA AG (DE) 2005-12-29 US disclosed
EP-1485352-B1 AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN SANOL ARZNEI SCHWARZ GMBH (DE) 2005-06-29 EP disclosed
EP-1520854-A2 Aza-Spirocompounds for the treatment of pain SCHWARZ PHARMA AG (DE) 2005-04-06 EP disclosed
EP-1485352-A1 AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN SCHWARZ PHARMA AG (DE) 2004-12-15 EP disclosed
WO-2003074486-A1 AZASPIRO COMPOUNDS FOR THE TREATMENT OF PAIN SCHWARZ PHARMA AG (DE) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288351-A1 Azaspiro compounds for the treatment of pain TPMT, P2RY13, OPRL1 CYP3A4 1954/4885CYP2C19 2524/4885HIF1A 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.